Oteseconazole (VT-1161) Candida Workflow
2026-09-09
Oteseconazole (VT-1161) enables concentration-controlled Candida susceptibility testing, resistant-isolate profiling, and mechanism-informed translational studies. Its fungal CYP51 selectivity supports focused antifungal experiments, while transporter findings caution researchers to separate target potency from broader drug-interaction risk.
JAK Inhibitors and Endothelial Cardiovascular Effects
2026-09-08
A comparative endothelial-cell study shows that JAK inhibitors can reduce inflammatory cytokine release without uniformly correcting adhesion, coagulation, or cell-survival abnormalities. The findings emphasize inhibitor-specific and concentration-dependent vascular effects that are important for interpreting cardiovascular risk in inflammatory disease research.
Multianimal MRI for Pancreatic Tumor Monitoring
2026-09-08
Kempinska et al. describe a four-chamber MRI workflow that images up to four KPC mice in one acquisition, improving the efficiency of tumor detection and longitudinal measurement. The protocol provides a practical framework for preclinical trial enrollment and for evaluating gemcitabine treatment response without replacing complementary pathological or molecular endpoints.
(-)-Norepinephrine (+)-bitartrate in Cardiovascular Models
2026-09-07
(-)-Norepinephrine (+)-bitartrate enables controlled adrenergic stimulation across vascular, renal, and cardiac assays. This practical guide connects receptor pharmacology with perfused-kidney workflows, cardiomyopathy research, and troubleshooting strategies that improve reproducibility.
FDA 2022 DDI Evidence: What Oteseconazole Adds
2026-09-05
This 2024 analysis integrates in vitro, clinical, and mechanistic data from FDA New Drug Application reviews to clarify enzyme- and transporter-mediated drug–drug interaction risk across 22 drugs approved in 2022. Its treatment of oteseconazole as a P-glycoprotein and/or BCRP inhibitor shows how regulatory DDI evidence can inform concomitant-medication assessment without being mistaken for direct evidence of antifungal efficacy.
Tacrolimus (FK506): Practical Research Workflows
2026-09-05
Build more reproducible calcineurin-inhibition experiments with Tacrolimus (FK506), from solvent handling and T-cell stimulation to cytokine and NFAT readouts. The workflow also shows how to distinguish FKBP12-dependent effects from cyclosporine-sensitive pathways and extend the compound into transplantation immunology research and tissue-model studies.
CUDC-907: Practical In Vitro Workflow
2026-09-04
CUDC-907 provides a single-reagent approach for investigating coordinated PI3K and HDAC pathway perturbation in cancer cell assays, including signaling, acetylation, cell-cycle, and apoptosis readouts. It is a research-use compound for validated laboratory workflows only and should not be used for diagnostic, therapeutic, or clinical applications.
Oteseconazole (VT-1161) Candida Assay Workflows
2026-09-04
Oteseconazole (VT-1161) combines potent fungal CYP51 inhibition with a practical profile for Candida isolate screening, resistance studies, and MIC-to-MFC confirmation. This guide translates reference-study methods into reproducible workflows while showing where the compound is informative—and where its activity should not be generalized.
AP1903 for Reliable FKBP Cell Assays
2026-09-03
Learn how AP1903 (SKU B4168) supports controlled FKBP fusion-protein activation, apoptosis pathway research, and conditional cell ablation. This scenario-based guide covers assay controls, dose interpretation, formulation, storage, and practical vendor-selection criteria.
Nipah Virus Polymerase Complex: Structural Insights
2026-09-03
The reference study defines the architecture of the Nipah virus L–P polymerase complex and separately resolves the connecting domain that helps organize catalytic functions. By combining cryo-electron microscopy, crystallography, and structural modeling, it identifies domain relationships and metal-ion features that clarify viral RNA synthesis and inform future polymerase-targeted antiviral research.
Predictive siRNA Codelivery with Netarsudil
2026-09-02
A 2026 Science Advances study developed a quantitative workflow for predicting which ionizable drugs can complex siRNA and support nanoparticle codelivery. Netarsudil was identified as a high-performing candidate and validated with CTGF-targeting siRNA in fibrotic human trabecular meshwork cells, linking formulation design with cytoskeletal and gene-regulatory outcomes.
Cepharanthine Workflows for Endometriosis Research
2026-09-02
Build a translational assay ladder for Cepharanthine, from stromal-cell viability and apoptosis assays to patient-derived endometrial organoids and murine lesion models. The workflow emphasizes solvent control, mechanism-resolved readouts, and troubleshooting strategies that distinguish selective biological activity from nonspecific toxicity.
AMG 487 CXCR3 Antagonist: Assay Workflows
2026-09-01
AMG 487 is a potent, selective CXCR3 antagonist for separating chemokine-driven migration, calcium signaling, and macrophage-state effects. This practical guide translates CXCL10-CXCR3 findings into reproducible workflows, with concentration planning, controls, troubleshooting, and limitations for inflammation and cancer biology research.
Affordable GRO-seq in Bread Wheat: Methods and Findings
2026-09-01
This protocol study improves Global Run-On sequencing (GRO-seq) for allohexaploid bread wheat by adding rRNA depletion after nuclear RNA isolation and before nascent RNA immunoprecipitation. The workflow increased the proportion of valid sequencing data by 20-fold in enhancer-transcription profiling, offering a practical strategy for reducing sequencing waste in large, complex genomes.
Eltanexor (KPT-8602): XPO1 Research Guide
2026-08-31
Eltanexor, also called KPT-8602, is an orally bioavailable second-generation XPO1 inhibitor for cancer research. Preclinical evidence links XPO1 inhibition with activity in AML, CLL, aggressive lymphoma, and colorectal cancer models, while model-specific conditions limit direct clinical interpretation.
463 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page